Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30658613 | 1.00 | DHODH (0.39) | DHODHCYP17A1CYP1A2TRPV1HSD11B1 | |
| SCHEMBL23249649 | 0.98 | DHODH (0.38) | DHODHCYP17A1CYP1A2TRPV1HSD11B1 | |
| Magnesium SCHEMBL29514747 | 0.98 | DHODH (0.38) | DHODHCYP17A1CYP1A2TRPV1HSD11B1 | |
| SCHEMBL28411296 | 0.84 | DHODH (0.38) | DHODHCYP17A1CYP1A2TRPV1HSD11B1 | |
| SCHEMBL29101572 | 0.84 | DHODH (0.38) | DHODHCYP17A1CYP1A2TRPV1HSD11B1 | |
| SCHEMBL29437213 | 0.84 | DHODH (0.42) | DHODHCYP17A1CYP1A2TRPV1HSD11B1 | |
| SCHEMBL29101597 | 0.84 | DHODH (0.40) | DHODHCYP17A1CYP1A2TRPV1HSD11B1 | |
| SCHEMBL12528202 | 0.84 | DHODH (0.42) | DHODHCYP17A1CYP1A2TRPV1HSD11B1 | |
| SCHEMBL22315221 | 0.81 | DHODH (0.37) | DHODHCYP17A1CYP1A2TRPV1OPRL1 | |
| SCHEMBL3418088 | 0.80 | DHODH (0.38) | DHODHCYP17A1CYP1A2TRPV1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116535388-B | Chlorantraniliprole Process for the preparation of amides | 江苏七洲绿色科技研究院有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-116535388-A | Preparation method of chlorantraniliprole | 江苏七洲绿色科技研究院有限公司 | 2023-08-04 | — | — | CN | claimed |
| CN-114641471-B | Process for the preparation of 5-bromo-2- (3-chloro-pyridin-2-yl) -2H-pyrazole-3-carboxylic acid | FMC公司 | 2025-05-23 | — | — | CN | disclosed |
| EP-4219455-B1 | METHODS FOR THE PREPARATION OF A HALOGENATED PYRAZOLE | FMC CORP (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-116535388-B | Chlorantraniliprole Process for the preparation of amides | 江苏七洲绿色科技研究院有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-116535388-B | Chlorantraniliprole Process for the preparation of amides | 江苏七洲绿色科技研究院有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-119039270-A | Process for the preparation of 5-bromo-2- (3-chloro-pyridin-2-yl) -2H-pyrazole-3-carboxylic acid | FMC公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240300901-A1 | METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID | FMC IP TECHNOLOGY GMBH (CH) | 2024-09-12 | — | — | US | disclosed |
| CN-114650987-B | Process for the preparation of 5-bromo-2- (3-chloro-pyridin-2-yl) -2H-pyrazole-3-carboxylic acid | FMC公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20240132462-A1 | METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE | FMC IP TECHNOLOGY GMBH (CH) | 2024-04-25 | — | — | US | disclosed |
| EP-4043451-B1 | METHODS FOR THE PREPARATION OF AN INTERMEDIATE IN THE SYNTHESIS OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID | FMC CORP (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-102746327-A | Method for producing hydrazine compound,and production intermediates of hydrazine compound and methods of producing the intermediates | SUMITOMO CHEMICAL CO | 2012-10-24 | — | — | CN | disclosed |
| EP-2481724-A1 | Method for producing hydrazine compound, and production intermediates of hydrazine compound and methods for producing the intermediates | Sumitomo Chemical Company, Limited (JP) | 2012-08-01 | — | — | EP | disclosed |
| EP-2481724-A1 | Method for producing hydrazine compound, and production intermediates of hydrazine compound and methods for producing the intermediates | Sumitomo Chemical Company, Limited (JP) | 2012-08-01 | — | — | EP | disclosed |
| CN-101784537-A | Method for producing hydrazine compound, intermediate for producing hydrazine compound, and method for producing intermediate | SUMITOMO CHEMICAL CO | 2010-07-21 | — | — | CN | disclosed |
| US-20100145059-A1 | METHOD FOR PRODUCING HYDRAZINE COMPOUND,AND PRODUCTION INTERMEDIATES OF HYDRAZINE COMPOUND AND METHODS OF PRODUCING THE INTERMEDIATES | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-20100145059-A1 | METHOD FOR PRODUCING HYDRAZINE COMPOUND,AND PRODUCTION INTERMEDIATES OF HYDRAZINE COMPOUND AND METHODS OF PRODUCING THE INTERMEDIATES | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-20100145059-A1 | METHOD FOR PRODUCING HYDRAZINE COMPOUND,AND PRODUCTION INTERMEDIATES OF HYDRAZINE COMPOUND AND METHODS OF PRODUCING THE INTERMEDIATES | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-06-10 | — | — | US | disclosed |
| EP-2189455-A1 | PROCESS FOR PRODUCTION OF HYDRAZINE COMPOUND, INTERMEDIATE FOR PRODUCTION OF HYDRAZINE COMPOUND, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATE | Sumitomo Chemical Company, Limited (JP) | 2010-05-26 | — | — | EP | disclosed |
| EP-2189455-A1 | PROCESS FOR PRODUCTION OF HYDRAZINE COMPOUND, INTERMEDIATE FOR PRODUCTION OF HYDRAZINE COMPOUND, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATE | Sumitomo Chemical Company, Limited (JP) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145059-A1 | METHOD FOR PRODUCING HYDRAZINE COMPOUND,AND PRODUCTION INTERMEDIATES OF HYDRAZINE COMPOUND AND METHODS OF PRODUCING THE INTERMEDIATES | HPD, CYP51A1, HAAO | DHODH 17/4885CYP17A1 438/4885CYP1A2 83/4885 |
| US-20240300901-A1 | METHODS FOR THE PREPARATION OF 5-BROMO-2-(3-CHLORO-PYRIDIN-2-YL)-2H-PYRAZOLE-3-CARBOXYLIC ACID | TUBA3C, KYAT3, AADAC | DHODH 410/4885CYP17A1 1696/4885CYP1A2 48/4885 |
| US-20240132462-A1 | METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE | CPS1, TERT, PRMT5 | DHODH 939/4885CYP17A1 3623/4885CYP1A2 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.